Lynk Pharmaceuticals Announces Completion of Patient Enrollment in Phase III Clinical Trial of Zemprocitinib for Ankylosing Spondylitis
- Lynk Pharmaceuticals completed patient enrollment on July 9 for the Phase III trial of zemprocitinib capsules to treat active ankylosing spondylitis .
- The Phase III trial is randomized, double-blind, placebo-controlled, and multicenter, focusing on the efficacy and safety of zemprocitinib in active AS.
- A total of 352 patients are enrolled, and the study continues with treatment, follow-up, and data collection as planned.
- The enrollment completion is a key milestone toward providing a new oral treatment for this chronic inflammatory disease.
37 Articles
37 Articles
Henry Herald
Lynk Pharmaceuticals Announces Completion of Patient Enrollment in Phase III Clinical Trial of Zemprocitinib for Ankylosing Spondylitis
HANGZHOU, China and SHANGHAI and BOSTON, July 14, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced that patient enrollment was completed on July 9 in…
Lynk Pharmaceuticals completes Phase III enrollment for spondylitis drug
HANGZHOU, China and SHANGHAI and BOSTON, July 15, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced that patient enrollment was completed on July 9 in the Phase III clinical trial evaluating its core product zemprocitinib capsules for the treatment of active ankylosing spondylitis (AS). The successful comp…
Coverage Details
Bias Distribution
- 71% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
